Publish time: 2023-04-13 00:00:00
12T-1100604
Know-how
The human heart is more susceptible to drug toxicants compared to other organs in the human body. Induced pluripotent stem cells (iPSC)-derived cells furnish a new paradigm for modelling diseases and screening drugs in a more physiologically relevant context than current methods, and will play a significant role in ushering the era of precision medicine. We have screened 1,000 healthy Taiwanese subjects, which were analyzed for representative high-frequency HLA homozygous genotypes in the Taiwanese population, and detected 13 HLA homozygous “super donors”. We currently have generated and characterized these 13 HLA homozygous iPSC, and successfully differentiated all of them into cardiomyocytes. This platform could be used across all stages of the R&D process, from high throughput screening for novel drug candidates and targets, to predicting drug toxicity and efficacy in the clinic.
- These 13 iPSC cell lines were generated by a team with 8 years of experience in the field of iPSC. The team is led by Dr. Hsieh, Patrick Ching-Ho, Distinguished Research Fellow in the Institute of Biomedical Sciences, Academia Sinica. All cell lines are fully characterized, and serve as high-quality research biomaterials for various purposes.
- The HLA-homozygous iPSCs are representative as high-frequency HLA homozygous genotypes in the Taiwanese population, which provides a more relevant database for population-based disease mechanism studies and novel drug discoveries.
- Academic research: Regenerative cell therapy
- Drug development: Drug screening, mechanism and toxicity testing
- Medical application: Precision medicine
Hsieh, Patrick Ching-Ho
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

HLA-homozygous iPSCs (THTC-01~THTC-013)